+ND Capital
Venture capitalWoodside · Seed–Late Stage · 17 people tracked
Also known as NANODIMENSION AG · NANODIMENSION, INC.
Investment thesis
+ND Capital was founded on the conviction that major breakthroughs would emerge at the nanoscale and that deep scientific expertise is needed to distinguish real science from science fiction. The firm invests in nanotechnology and deep-science ventures, with a strong emphasis on US-based opportunities alongside its Swiss roots, maintaining a presence spanning Switzerland and the Boston/Silicon Valley areas.
Source: firm website, verified Aug 11, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 21 of 32 portfolio companiesBiotech ×17Healthtech ×8Deep Tech ×7AI & Machine Learning ×5Medical Devices ×5Digital Health ×3Hardware ×3Cleantech ×2
HQs:United States×9Switzerland×2
Investments · 32 tracked
founders shown can be your intro pathBy year:2021 · 12019 · 12016 · 13 dated
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Rob Chess(Director)
BoardKeith Crandell(Director)Paul Conley(Director)
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
BiotechSouth San Francisco, US
Cameron Wheeler(Director)Elaine Jones(Director)Wendye Robbins(Executive Officer, Director)William Slattery(Director)James Scopa(Director)
BoardLuke Evnin(Director)
Board seatPeter Van Vlasselaer· per SEC Form D · $50M raise · filed Oct 2019
BiotechNew York, US
David Darst(Chief Operating Officer)Shahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)Isabel Kurth(Vice President - Research)Masoud Tavazoie(Chief Scientific Officer)
Board seatPeter Van Vlasselaer· per SEC Form D · $11M raise · filed Feb 2021
ALLInBio develops a precision immunology approach to identify and treat patients genetically predisposed to rapid progression of chronic inflammatory diseases.
BiotechHealthtechMedical Devices
Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Justin Farlow(Co-founder)Colin Farlow(Co-founder)
Amazentis is a Swiss longevity-biotech company that developed Mitopure, a proprietary high-purity form of the postbiotic Urolithin A shown in human trials to support mitochondrial health via mitophagy.
BiotechLongevityWellness & FitnessLausanne, CH
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
BiotechHealthtech
Constructive develops synthetic biology technology using recoded genomes and engineered tRNAs to incorporate novel chemical building blocks into proteins, enabling new therapeutics, materials, and manufacturing applications.
BiotechDeep TechNew Materials
Crocus Technology, now part of Allegro MicroSystems, develops XtremeSense TMR (Tunnel Magnetoresistance) magnetic sensing technology used in integrated current and position sensor ICs.
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)Daniel Blessing(Chief Scientific Officer (CSO) & Co-founder)Richard Law(Chief Business Officer (CBO))Eric Adam(Chief Operating Officer (COO))Jordan Shin(Chief Medical Officer (CMO))Jérôme Andries(Chief Financial Officer (CFO))
Manus develops and manufactures bioalternatives—sustainable ingredients produced using engineered microbes and cell factories—for use in food, flavor, fragrance, and other consumer products.
BiotechCleantechAugusta, US
Richard Goldstein(Director)Ajikumar Parayil(Executive Officer, Director)Gregory Stephanopoulos(Director)
BoardJason Whaley(Director)Carsten Boers(Director)
Notify Therapeutics is developing a non-hormonal female fertility treatment that targets the hormone-independent phase of early ovarian follicle development, aimed at infertile women who do not respond to standard hormone therapy.
BiotechDigital HealthFemTech
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Co-founder)in
Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome.
BiotechDigital HealthHealthtechMedical DevicesCalifornia, US
Jeroen(Co-founder and President)Ivan Dimov(Executive Officer, Director)Nathaniel Fernhoff(Executive Officer, Director)
BoardAlex Kolicich(Director)Jonathan MacQuitty(Director)
Spark develops LE-UWB, a wireless technology that delivers ultra-low latency and high throughput for applications including gaming, audio, industrial IoT, and medical devices.
Deep TechHardwareIoT
Visby Medical manufactures at-home PCR tests for sexually transmitted infections, providing FDA-authorized results in 30 minutes.
Digital HealthFemTechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioAlumniNYSE: AZNTwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesTwist Bioscience · biospace.com · Jul 16, 2026
Orca Bio · healthcaremea.com · Jul 7, 2026
Lightcast · kb.lightcast.io · Jul 2, 2026
Octant Bio · salestools.io · Oct 23, 2025
Frequently asked questions
- What stage does +ND Capital invest at?
- +ND Capital invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is +ND Capital's typical check size?
- +ND Capital typically writes checks of $540K – $5.4M.
- What sectors does +ND Capital focus on?
- +ND Capital focuses on Biotech, Deep Tech, Energy, Hardware, Healthtech, New Materials, Semiconductors.
- Where is +ND Capital located?
- +ND Capital is headquartered in Woodside, CH.
- Does +ND Capital lead rounds?
- Yes, +ND Capital leads investment rounds.
Co-investors · 15
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
Paladin Capital Group is a global investment firm backing innovative companies in cybersecurity, secure AI, and deep tech.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
▶3 more co-investors
Firms observed investing alongside +ND Capital, from public investor directories. Shared companies are the overlap with +ND Capital's recorded portfolio.
Similar investors
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Blindspot Ventures is an infrastructure-focused technology investment fund that backs founders building foundational platforms, systems, and technologies for critical industries.
Safar Partners is an early-stage technology investment firm that backs startups spun out of leading research universities, primarily MIT, Harvard, and the University of Rochester.
Quad Ventures is a Korean venture capital firm that identifies founders driving lifestyle and industry change and invests in the technologies enabling them, backing early-stage startups across advanced technology sectors.